<bill session="116" type="s" number="64" updated="2019-06-06T09:20:06Z">
  <state datetime="2019-01-09">REFERRED</state>
  <status>
    <introduced datetime="2019-01-09"/>
  </status>
  <introduced datetime="2019-01-09"/>
  <titles>
    <title type="official" as="introduced">A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.</title>
    <title type="short" as="introduced">Preserve Access to Affordable Generics and Biosimilars Act</title>
    <title type="short" as="introduced">Preserve Access to Affordable Generics and Biosimilars Act</title>
    <title type="display">Preserve Access to Affordable Generics and Biosimilars Act</title>
  </titles>
  <sponsor bioguide_id="K000367"/>
  <cosponsors>
    <cosponsor bioguide_id="C001035" joined="2019-06-05"/>
    <cosponsor bioguide_id="C001096" joined="2019-03-28"/>
    <cosponsor bioguide_id="D000563" joined="2019-04-10"/>
    <cosponsor bioguide_id="E000295" joined="2019-01-28"/>
    <cosponsor bioguide_id="G000386" joined="2019-01-09"/>
    <cosponsor bioguide_id="L000174" joined="2019-01-28"/>
    <cosponsor bioguide_id="V000128" joined="2019-06-05"/>
  </cosponsors>
  <actions>
    <action datetime="2019-01-09">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2019-01-09" state="REFERRED">
      <text>Read twice and referred to the Committee on the Judiciary.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSJU" name="Senate Judiciary" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="h" session="116" relation="unknown" number="2375"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Civil actions and liability"/>
    <term name="Competition and antitrust"/>
    <term name="Contracts and agency"/>
    <term name="Federal Trade Commission (FTC)"/>
    <term name="Intellectual property"/>
    <term name="Judicial review and appeals"/>
    <term name="Licensing and registrations"/>
    <term name="Marketing and advertising"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <committee-reports/>
</bill>
